These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 14527402)

  • 1. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.
    Burgess AW; Cho HS; Eigenbrot C; Ferguson KM; Garrett TP; Leahy DJ; Lemmon MA; Sliwkowski MX; Ward CW; Yokoyama S
    Mol Cell; 2003 Sep; 12(3):541-52. PubMed ID: 14527402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand-induced ErbB receptor dimerization.
    Lemmon MA
    Exp Cell Res; 2009 Feb; 315(4):638-48. PubMed ID: 19038249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding specificities and affinities of egf domains for ErbB receptors.
    Jones JT; Akita RW; Sliwkowski MX
    FEBS Lett; 1999 Mar; 447(2-3):227-31. PubMed ID: 10214951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2.
    Nagy P; Vereb G; Sebestyén Z; Horváth G; Lockett SJ; Damjanovich S; Park JW; Jovin TM; Szöllosi J
    J Cell Sci; 2002 Nov; 115(Pt 22):4251-62. PubMed ID: 12376557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity.
    Danielsen AJ; Maihle NJ
    Exp Cell Res; 2002 Apr; 275(1):9-16. PubMed ID: 11925101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand-independent dimerization of oncogenic v-erbB products involves covalent interactions.
    Adelsman MA; Huntley BK; Maihle NJ
    J Virol; 1996 Apr; 70(4):2533-44. PubMed ID: 8642683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular domains drive homo- but not hetero-dimerization of erbB receptors.
    Ferguson KM; Darling PJ; Mohan MJ; Macatee TL; Lemmon MA
    EMBO J; 2000 Sep; 19(17):4632-43. PubMed ID: 10970856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear localization and possible functions of receptor tyrosine kinases.
    Carpenter G
    Curr Opin Cell Biol; 2003 Apr; 15(2):143-8. PubMed ID: 12648669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.
    Ferguson KM; Berger MB; Mendrola JM; Cho HS; Leahy DJ; Lemmon MA
    Mol Cell; 2003 Feb; 11(2):507-17. PubMed ID: 12620237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ErbB Receptors and Cancer.
    Wang Z
    Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
    Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ErbB receptors and their ligands in cancer: an overview.
    Normanno N; Bianco C; Strizzi L; Mancino M; Maiello MR; De Luca A; Caponigro F; Salomon DS
    Curr Drug Targets; 2005 May; 6(3):243-57. PubMed ID: 15857286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm.
    Boerner JL; Danielsen A; Maihle NJ
    Exp Cell Res; 2003 Mar; 284(1):111-21. PubMed ID: 12648470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
    Graus-Porta D; Beerli RR; Daly JM; Hynes NE
    EMBO J; 1997 Apr; 16(7):1647-55. PubMed ID: 9130710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (EGFR) signaling in cancer.
    Normanno N; De Luca A; Bianco C; Strizzi L; Mancino M; Maiello MR; Carotenuto A; De Feo G; Caponigro F; Salomon DS
    Gene; 2006 Jan; 366(1):2-16. PubMed ID: 16377102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGF-ERBB signalling: towards the systems level.
    Citri A; Yarden Y
    Nat Rev Mol Cell Biol; 2006 Jul; 7(7):505-16. PubMed ID: 16829981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor.
    Schlessinger J
    Cell; 2002 Sep; 110(6):669-72. PubMed ID: 12297041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting ErbB receptors in high-grade glioma.
    Berezowska S; Schlegel J
    Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic monoclonal antibodies for the ErbB family of receptor tyrosine kinases.
    Zhang H; Richter M; Greene MI
    Cancer Biol Ther; 2003; 2(4 Suppl 1):S122-6. PubMed ID: 14508089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.